Search results for "coagulation factor"

showing 10 items of 45 documents

Spontaneous chronic subdural hematomas in young adults with a deficiency in coagulation factor XIII. Report of three cases

2005

✓ Chronic subdural hematomas (SDHs) generally occur in elderly patients. Its pathogenesis is usually related to head trauma with tearing and rupture of the bridging veins, although in some cases a history of trauma is not recognizable. There are many reports regarding the association between spontaneous chronic SDHs and an alteration in coagulative parameters. A coagulative disorder should be suspected when an unexplained hemorrhage occurs, especially in a young patient. The authors report on three young men with a deficiency in coagulation factor XIII (FXIII) who underwent surgery for chronic SDHs. The role of FXIII in the pathogenesis of chronic SDH is emphasized. In patients with unexpla…

AdultMalemedicine.medical_specialtyPediatricsCoagulation Factor Deficiencysubdural hematornaHead traumacoagulopathyPathogenesisHematomamedicineCoagulopathyHumansPostoperative CareVascular diseasebusiness.industryHeadachefactor XIIIFactor XIIImedicine.diseaseFactor XIII DeficiencyMagnetic Resonance ImagingSurgeryCoagulative necrosisHematoma Subdural Chronicbusinessmedicine.drug
researchProduct

Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patient…

2008

We recommend prophylaxis in haemophilic children with an inhibitor as a way of preventing the musculoskeletal impairment that is likely to affect them. This approach has been used for children without inhibitors with excellent results. If prophylaxis is not feasible, we suggest that intensive on-demand treatment should be given. Two agents, recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (aPCC), are currently used to control haemostasis either for prophylaxis or intensive on-demand treatment. As it is recombinant, rFVIIa would seem more appropriate to be employed in children. aPCC could be used in adults, or in the event of an unsatisfactory response to rF…

AdultMalemedicine.medical_specialtyPediatricsTime FactorsEvidence-based practiceAdolescentFactor VIIaHemophilia AHaemophiliaFactor IXYoung AdultHemarthrosismedicineOrthopaedic proceduresHumansPain ManagementOrthopedic ProceduresChildIntensive care medicinePhysical Therapy ModalitiesGenetics (clinical)Randomized Controlled Trials as TopicRetrospective StudiesHaemophilic arthropathySynovitisBlood Coagulation Factor InhibitorsCoagulantsbusiness.industryMusculoskeletal impairmentHematologyGeneral MedicinePerioperativemedicine.diseaseSkeletal maturityBlood Coagulation FactorsRecombinant ProteinsCartilageTreatment OutcomeChild PreschoolPractice Guidelines as TopicbusinessPROTHROMBIN COMPLEXHaemophilia : the official journal of the World Federation of Hemophilia
researchProduct

Extracorporeal circuit heparinization in selective low density lipoprotein apheresis: changes in patient hemostasis and low molecular weight heparin …

1993

Treatment by low density lipoprotein (LDL) apheresis using dextran sulfate columns (DSC) leads to hemostasis alterations with prolonged activated partial thromboplastin time (APTT) of more than 120 seconds. In order to explain this hypocoagulability, we studied hemostasis parameters both in patients and in the extracorporeal circulation (ECC). Hemostasis changes are first related to unfractionated heparin (UFH)—needed to avoid circuit coagulation—which leads to high residual heparinemia in the patient (more than 3 times the recommended level for therapeutic use). Second, the hypocoagulability is induced by a coagulation factor decrease (primarily factors V, VIH, and X) mainly due to an adso…

Adultmedicine.medical_specialtyExtracorporeal Circulationmedicine.drug_classLow molecular weight heparinHyperlipoproteinemia Type IIInternal medicinemedicineHumansHemostasismedicine.diagnostic_testbusiness.industryExtracorporeal circulationAnticoagulantDextran SulfateNadroparinHematologyGeneral MedicineHeparinMiddle AgedBlood Coagulation FactorsSurgeryLipoproteins LDLApheresisLDL apheresisHemostasisCardiologyBlood Component RemovalbusinessPartial thromboplastin timemedicine.drugJournal of clinical apheresis
researchProduct

Clinical and echographical control protocol of haemarthrosis in haemophilia patients with inhibitors: evaluation of the efficacy of recombinant facto…

2008

Summary.  The intention of the ‘clinical and echographical protocol of evaluation the efficacy of recombinant activated factor VII in the haemarthrosis’ (EFFISEVEN protocol) was to provide an extensive study of the evolution of haemarthrosis, and second, of its repercussions on the degenerative process of joints. The clinical evaluation of haemarthroses and their evolution is based on a well-established methodology, although very few studies have sought to determine the correlation between pain, mobility and the objective data regarding the haemorrhage. We believe that it is necessary to unify criteria and that the EFFISEVEN protocol may contribute data that improve standards which, in turn…

Adultmedicine.medical_specialtyTime FactorsAdolescentObjective dataFactor VIIaHemophilia AHaemophiliaDrug Administration ScheduleYoung AdultClinical ProtocolsHemarthrosisActivated factor VIIHumansMedicineRange of Motion ArticularIntensive care medicineGenetics (clinical)UltrasonographyProtocol (science)Blood Coagulation Factor Inhibitorsbiologybusiness.industryObjective methodHematologyGeneral Medicinemedicine.diseaseArthralgiaBlood Coagulation FactorsRecombinant ProteinsPatient managementEuropeRecombinant factor VIIaQuality of Lifebiology.proteinPhysical therapyBlood Coagulation TestsbusinessClinical evaluationHaemophilia
researchProduct

VITAMIN K-INDUCED MODIFICATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY

2008

Summary.  Background: Combined vitamin K-dependent clotting factor (VKCF) deficiency type 2 (VKCFD2) is a rare bleeding disorder caused by mutated vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) gene. Methods and results: An Italian patient with moderate to severe bleeding tendency was genotyped, and found to be homozygous for the unique VKORC1 mutation (Arg98Trp) so far detected in VKCFD2. The activity levels of VKCFs were differentially reduced, and inversely related to the previously estimated affinity of procoagulant factor propeptides for the γ-carboxylase. The normal (factor IX) or reduced antigen levels (other VKCFs) produced a gradient in specific activities. Vitamin K su…

Adultmedicine.medical_specialtycoagulation factor levelsVitamin KProtein SMixed Function OxygenasesTissue factorchemistry.chemical_compoundInternal medicineVitamin K Epoxide ReductasesmedicineVKCFD2HumansFactor IXClotting factorCoagulation factor levels; Thrombin generation; Vitamin K supplementation; VKCFD2; VKORC1 mutation;biologyFactor VIIChemistryFactor XHomozygotevitamin K supplementationHematologyBlood Coagulation DisordersEndocrinologyTreatment OutcomeCoagulationthrombin generationImmunologyMutationbiology.proteinFemaleBlood Coagulation TestsVKCFD2 VKORC1 mutation coagulation factor levels thrombin generation vitamin K supplementationProtein Cmedicine.drugHalf-LifeVKORC1 mutation
researchProduct

Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.

1997

This study was conducted to identify the mechanisms responsible for coagulative and fibrinolytic alterations and to study the effects of a short-term treatment with low-dose heparin on hemostatic abnormalities in obese non-insulin-dependent diabetes mellitus (NIDDM) patients. Four groups of age- and sex-matched patients were studied: (1) lean nondiabetic subjects (n = 30) with a body mass index (BMI) less than 25 kg/m2 (lean control subjects), (2) obese nondiabetic subjects (n = 30) with a BMI greater than 30 kg/m2 (obese control subjects), (3) lean NIDDM patients (n = 30), and (4) obese NIDDM patients (n = 30). All subjects were tested on the following parameters: fibrinogen, factor VII, p…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenTissue plasminogen activatorBody Mass Indexchemistry.chemical_compoundEndocrinologyInternal medicineFibrinolysismedicineHumansInsulinObesityBlood CoagulationHemostasisFactor VIIbusiness.industryHeparinFibrinolysisnutritional and metabolic diseasesAnticoagulantsHeparinMiddle AgedLipidsBlood Coagulation FactorsEndocrinologychemistryDiabetes Mellitus Type 2HemostasisCase-Control StudiesFemalebusinessPlasminogen activatorBody mass indexmedicine.drugMetabolism: clinical and experimental
researchProduct

Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response

2000

Objectives: The aim of the present study was to evaluate the effects of pravastatin treatment on lipid, inflammation, and coagulation parameters in patients suffering from myocardial infarction with or without carotid atherosclerotic lesions (groups 1 and 2, respectively). Methods: In the first phase of the study, a cross-sectional comparison of lipid, inflammation, and coagulation parameters was performed between the patients and the control group (group 3). Highly significant differences in these parameters were observed, especially in group 1. In the second phase of the study, we assessed the effects of a persistent reduction in cholesterol synthesis induced by increasing doses of pravas…

Blood GlucoseMalemedicine.medical_specialtyMyocardial InfarctionInflammationCoronary Artery DiseaseFibrinogenchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumansPharmacology (medical)PravastatinInflammationPharmacologyDose-Response Relationship DrugFactor VIIbusiness.industryCholesterolpravastatin inflammatory responseGeneral MedicineMiddle AgedBlood Coagulation FactorsCholesterolCross-Sectional StudiesEndocrinologyCoagulationchemistryCase-Control StudiesHemostasisFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptombusinessPravastatinmedicine.drugLipoproteinEuropean Journal of Clinical Pharmacology
researchProduct

Procoagulant activity during viral infections.

2017

The abundance of evidence suggest that inflammation of immune and non-immune cells may lead to an imbalance of the pro- and anti-coagulant state during viral infections. During systemic infections, the endothelium plays a critical role in regulating hemostasis, and severe imbalances of endothelial function and activation can contribute to organ failure. Viral infections may elevate plasma levels of procoagulant markers such as TAT and D-dimer TF-positive MPs as well as von Willebrand factor (vWF). Although multiple clinical studies are showing the association of viral infection and increased prothrombotic risk, the pathological mechanisms have not been fully identified for most viral infect…

Cell typeEndotheliumInflammation030204 cardiovascular system & hematologyThromboplastin03 medical and health sciences0302 clinical medicineImmune systemVon Willebrand factorvon Willebrand FactormedicineAnimalsHumansReceptorBlood CoagulationHemostasisbiologybusiness.industryToll-Like ReceptorsBlood Coagulation Factorsmedicine.anatomical_structureCoagulationVirus DiseasesHemostasisImmunologybiology.proteinmedicine.symptombusiness030217 neurology & neurosurgeryBiomarkersFrontiers in bioscience (Landmark edition)
researchProduct

Graphene coating obtained in a cold-wall CVD process on the Co-Cr Alloy (L-605) for medical applications

2021

Graphene coating on the cobalt-chromium alloy was optimized and successfully carried out by a cold-wall chemical vapor deposition (CW-CVD) method. A uniform layer of graphene for a large area of the Co-Cr alloy (discs of 10 mm diameter) was confirmed by Raman mapping coated area and analyzing specific G and 2D bands

ErythrocytesMicroscopeScanning electron microscope02 engineering and technologyChemical vapor deposition01 natural scienceslaw.inventionlcsh:ChemistryMiceCoated Materials BiocompatibleCoatinglawMaterials TestingComposite materiallcsh:QH301-705.5SpectroscopySettore CHIM/02 - Chimica Fisicagraphene coating ; biocompatibility ; cobalt chromium alloy ; cold wall chemical vapor deposition methodGeneral Medicine021001 nanoscience & nanotechnologyMicrostructureBlood Coagulation FactorsComputer Science ApplicationsGraphitePartial Thromboplastin TimeBiocompatibility0210 nano-technologyLayer (electronics)Blood PlateletsMaterials scienceCell SurvivalSurface PropertiesPrimary Cell Cultureengineering.material010402 general chemistryCobalt-chromium alloyGraphene coatingCold-wall chemical vapor deposition methodArticleCatalysisInorganic ChemistryAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyGrapheneOrganic Chemistrytechnology industry and agricultureNanoindentationPlatelet Activation0104 chemical scienceslcsh:Biology (General)lcsh:QD1-999NIH 3T3 CellsengineeringChromium AlloysVolatilization
researchProduct

Can we compare haemophilia carriers with clotting factor deficiency to male patients with mild haemophilia?

2020

Introduction Certain haemophilia carriers demonstrate an increased bleeding tendency, mainly related to clotting factor deficiency. No study has so far formally compared the bleeding phenotype of women and girls with mild FVIII or FIX deficiency and associated management with that of male patients affected by mild haemophilia A and B. Material and methods We retrospectively evaluated 44 women and girls with mild FVIII or FIX deficiency (FVIII or FIX 0.05-0.5 IU/mL) and 77 male patients with mild haemophilia A or B and compared them with respect to clotting factor level, age at and trigger for diagnosis, as well as treatment modalities. Results After excluding gender-related haemorrhagic sym…

FVIIImild haemophiliaAdultMalePediatricsmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesHeterozygoteAdolescentMucocutaneous zonecarriersPlasma factorAge at diagnosis030204 cardiovascular system & hematologyHaemophiliaHemophilia AHemostatics03 medical and health sciencesYoung Adult0302 clinical medicinecarrierhemic and lymphatic diseasesmedicineHumansDeamino Arginine VasopressinClotting factor deficiencyChildGenetics (clinical)AgedClotting factorAged 80 and overbusiness.industryFIXHematologyGeneral MedicineMiddle Agedmedicine.diseaseBlood Coagulation Factorsbleeding phenotypebleeding phenotype carriers FIX FVIII mild haemophiliaMale patientChild PreschoolMild haemophilia AFemalebusiness030215 immunologyHaemophilia : the official journal of the World Federation of HemophiliaREFERENCES
researchProduct